General education, not individual medical advice. Research checked November 9, 2026.
A decision about your life
A night of repeated waking can change the next day. Pain with sex can change a relationship. Hot flashes can interrupt a meeting, a walk or a quiet moment that used to belong to you. These are worthwhile reasons to seek care. You do not have to justify wanting relief by promising to live longer.
Menopausal hormone therapy can be useful, especially for bothersome hot flashes and night sweats. The central question is how its benefits and risks fit your symptoms, medical history, stage of menopause and preferences. Some people need a systemic treatment; others need a local treatment, a nonhormonal approach, or a different diagnosis. S01, S09
This issue is for women considering or revisiting that conversation. Some readers will be in perimenopause, some years beyond their last period, and some living with early or treatment-induced menopause. Trans men and nonbinary people may also experience menopause; the evidence and available guidance do not cover every treatment context equally.
Inside
Relief and timing · Perimenopause and early menopause · Routes and uterine protection · Interpreting WHI · Breast health · Vaginal and urinary symptoms · Brain health and longevity · Metabolic health and testosterone · Alternatives · Your appointment
General education, not a prescription or a substitute for individualized care. Research checked November 9, 2026.
Relief is a meaningful outcome
In the MsFLASH trial, 339 perimenopausal and postmenopausal women with bothersome hot flashes or night sweats were assigned low-dose oral estradiol, venlafaxine or placebo for eight weeks. The average starting frequency across participants was about eight episodes a day. Symptoms fell in all three groups, including placebo. S02
The between-group comparison matters: estradiol reduced daily symptom frequency by 2.3 more episodes than placebo, and venlafaxine by 1.8 more. The difference between the two active treatments was small and statistically uncertain. A short symptom trial cannot resolve breast cancer, clot or cardiovascular risks over years. S02
Hormone therapy is the most effective treatment for vasomotor symptoms overall, but response and tolerability vary. A review after starting or changing treatment is an opportunity to adjust the plan, not a test you can fail. S01
The stage changes the conversation
Perimenopause is not a steady decline
Symptoms, menstrual bleeding and contraceptive needs can overlap during the transition. Hormone levels fluctuate; the best plan may involve menstrual control and contraception as well as symptom relief. A 2026 clinician toolkit emphasizes this distinct physiology and the need to individualize care. It is a clinical perspective, not evidence that one hormonal strategy suits everyone. S18
Menopausal hormone therapy is not contraception. If pregnancy is possible and unwanted, ask for a contraceptive plan alongside symptom care. New or unusual bleeding should be assessed rather than automatically attributed to hormones. S11, S15
Premature ovarian insufficiency has different stakes
Loss of ovarian function before age 40 is called premature ovarian insufficiency, or POI. The joint guideline recommends hormone therapy, when appropriate, until the usual age of menopause even when symptoms are absent, followed by a new assessment. Evidence underlying some long-term recommendations is limited, but the clinical situation differs from starting hormones later in life for disease prevention. S11
A person who has had surgery or cancer treatment needs a plan shaped by that treatment and the reason for it. Symptoms can be real and severe even when systemic hormones are not an appropriate option.
Timing informs risk
For otherwise healthy people with bothersome symptoms, starting systemic therapy before age 60 or within about ten years of menopause generally has a more favorable benefit-risk balance than starting later. Baseline health still matters. A history of thrombosis or an estrogen-sensitive cancer is not cancelled by a younger age. S01, S15
The ELITE trial tested the timing hypothesis in 643 healthy women. Estradiol slowed progression of carotid artery wall thickness when begun less than six years after menopause, but not when begun ten or more years afterward. Coronary CT measures did not differ significantly. The trial measured a surrogate marker, not a reduction in heart attacks or deaths. S07
There is no rule that everyone must stop at 65. Continuing for persistent symptoms can be considered after review, while acknowledging the limited randomized evidence about extended treatment in older women. The aim is a reasoned decision with a follow-up plan, not an age-based deadline. S01
Route and uterine protection
Systemic therapy reaches the body through a pill or through the skin, such as a patch or gel. Local low-dose vaginal treatment is intended chiefly for vaginal and urinary symptoms. Some vaginal rings deliver systemic estrogen; the route alone does not tell you the exposure. These risk discussions should not be collapsed into a single category. S09, S15
Unopposed systemic estrogen stimulates the uterine lining and raises endometrial cancer risk. A patch does not remove the need for protection. The October 2026 estradiol-patch label retains that boxed warning. S15
In two large UK database studies, oral therapy was associated with higher odds of venous thrombosis than no recent exposure: adjusted odds ratio 1.58 (95% CI 1.52-1.64). Transdermal therapy was not associated with a statistically detectable increase: 0.93 (0.87-1.01). These observational findings support considering route, but cannot prove that a patch has zero risk or overrides a contraindication. S06
WHI in absolute numbers
The 2002 Women’s Health Initiative report studied oral conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) in 16,608 women aged 50-79 with a uterus. After an average of 5.2 years, overall risks exceeded benefits for the prevention question being tested. The trial was stopped early. S03
Reported differences per 10,000 person-years
These results still matter. They do not directly describe every modern preparation, every starting age, or low-dose vaginal estrogen. Conversely, a different formulation should not be assumed safe simply because this particular trial did not test it.
Bone protection is a real benefit of hormone therapy. If fracture prevention is the main goal, compare it with osteoporosis-specific options and the person’s fracture risk. The current estradiol-patch label advises considering non-estrogen medicines first when prescribing solely for osteoporosis prevention. S15
Breast risk needs precise language
Long-term WHI follow-up found different breast cancer results in its two trials. Among women with a uterus, prior assignment to oral conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) was associated with more breast cancers than placebo. Among women with a prior hysterectomy, assignment to CEE alone was associated with fewer. S04
| Trial population | Assigned hormones | Placebo |
|---|---|---|
| Uterus present CEE + MPA | 0.45% | 0.36% |
| Prior hysterectomy CEE alone | 0.30% | 0.37% |
For combined therapy the hazard ratio was 1.28 (95% CI 1.13-1.45); for estrogen alone it was 0.78 (0.65-0.93). Breast cancer mortality was lower in the estrogen-alone trial and not statistically different in the combined trial. These findings should not be turned into a recommendation to use estrogen to prevent breast cancer. S04
Personal and family history, prior biopsies, age, duration and the specific regimen belong in the discussion. Evidence about newer estrogen-progesterone combinations is not identical to WHI evidence. “Bioidentical” does not mean no breast risk.
Vaginal and urinary health deserve care
Dryness, burning, pain with penetration and some urinary symptoms can accompany the genitourinary syndrome of menopause, or GSM. They can affect comfort, intimacy and ordinary activities. Similar symptoms can also come from infections, skin conditions, pelvic-floor problems or other causes, so an assessment matters. S10
The 2025 AUA/SUFU/AUGS guideline identifies local low-dose vaginal estrogen as having the most robust evidence base. The 2020 NAMS statement also supports several hormonal options for moderate to severe GSM. Systemic therapy may not fully relieve local symptoms. S09, S10, S11
A progestogen is generally not required with low-dose vaginal estrogen. Long-term endometrial safety evidence from clinical trials is limited, and postmenopausal bleeding needs evaluation. If there is a history of breast cancer, involve the treating team in the decision, especially during endocrine therapy; do not transfer safety claims from the general population without qualification. S09
Brain health and a longer life
Difficulty concentrating can be distressing. Improved sleep and relief from night sweats may make daily life easier, but that does not establish hormone therapy as a treatment to prevent dementia. New cognitive symptoms also deserve consideration of sleep, mood, medicines and other health problems.
In WHIMS, 4,532 women aged at least 65 were assigned oral CEE plus MPA or placebo. Probable dementia occurred at rates of 45 versus 22 cases per 10,000 person-years, with a hazard ratio of 2.05 (95% CI 1.21-3.48). This is evidence of harm for that older population and regimen, not a direct estimate for starting treatment near menopause. S08
In the pooled WHI trials, all-cause mortality over 18 years was 27.1% after assignment to hormone therapy and 27.6% after placebo, HR 0.99 (0.94-1.03). That long follow-up included many years after trial treatment ended. Age-related patterns do not turn the overall study into proof that menopausal hormones extend everyone’s life. S05
A future study may sharpen these distinctions. Today, a sound reason to treat symptoms is enough; it need not carry an unsupported promise of preventing Alzheimer disease or reversing aging.
Metabolic health and testosterone
The menopause transition can coincide with changes in body composition, lipids and vascular health. It is a useful time to review blood pressure, smoking, movement, sleep and cardiometabolic risk. These concerns deserve attention whether or not hormone therapy is chosen. S20
A larger waist does not diagnose an “aromatase problem,” and an estradiol or testosterone result alone does not explain fatigue, weight change or low desire. For women, the evidence in this issue does not support suppressing estrogen production as a general metabolic strategy. Aromatase inhibitors have specific medical uses; they should not be repurposed into a self-directed menopause plan.
What about testosterone?
The 2019 international consensus identifies a narrow evidence-based use: postmenopausal hypoactive sexual desire disorder, persistently low desire that causes personal distress, after a formal assessment of biological, psychological and relationship factors. That is different from treating a laboratory value, general tiredness, cognition or longevity. The consensus notes a lack of safety data beyond 24 months. S12
Building a healthier metabolic environment and treating disruptive menopausal symptoms can proceed together. Neither requires framing a person’s body as a failure. The companion men’s issue examines the different evidence about testosterone, adiposity and aromatase; those findings should not be transferred wholesale to women.
More than one route to relief
If systemic hormones are not suitable or not wanted, there are evidence-based alternatives for hot flashes. Options include certain SSRIs or SNRIs, gabapentin, and menopause-specific cognitive behavioral therapy. The right choice depends on other symptoms, drug interactions and side effects. S14
Newer nonhormonal medicines target neurokinin signaling. Fezolinetant carries an FDA boxed warning for rare serious liver injury and requires liver blood-test monitoring. Elinzanetant was approved by the FDA on October 24, 2025. Its label requires liver tests before treatment and at three months, warns of daytime impairment and sleepiness, contraindicates use in pregnancy, and advises caution with a seizure history. Approval does not establish that it is best for every patient or directly equivalent to hormone therapy. S21, S22, S23
Bioidentical describes a molecule, not a guarantee
FDA-approved estradiol and progesterone products are available. Compounded preparations do not acquire proven safety because they are marketed as “natural” or individualized. ACOG recommends approved menopausal therapies over routinely using compounded alternatives when approved formulations exist. S13
Exercise, nourishing food and sleep support broader health and can be worth pursuing for their own benefits. They should not be sold as guaranteed replacements for effective symptom treatment. Nor should supplements be assumed to treat hot flashes reliably because they are sold without a prescription. S14
Make the appointment useful
- The problem I want to improve
Which symptoms disrupt sleep, work, comfort, relationships or activities? How often?
- The history that changes the choice
Last menstrual period, bleeding pattern, uterus and ovary surgery, pregnancy possibility, cancer history, clotting or cardiovascular history, liver disease, medications and family history.
- The proposed plan
Why this formulation and route? Do I need uterine protection? Are local treatment or nonhormonal options a better fit?
- How we will review it
What improvement should I expect? Which adverse effects matter? When do we reassess? How do we change or discontinue the plan if it is not helping?
Seek urgent medical care for sudden chest pain or shortness of breath, stroke-like symptoms or a painful swollen leg. Arrange prompt assessment for postmenopausal bleeding rather than assuming it is harmless.
The goal is a plan you understand, with benefits that matter to you and risks discussed honestly. Choosing treatment, declining it or changing course can each be a reasonable decision.
Read the evidence
Source access and limitations are included so readers can judge what was checked.
S01: The 2022 hormone therapy position statement
The North American Menopause Society, 2022. Read source
Consensus guideline; PubMed abstract and society highlights reviewed. Individualized symptom treatment; age and timing; continued reassessment. Full guideline could not be retrieved in this run.
S02: Low-dose estradiol and venlafaxine for vasomotor symptoms
Joffe et al., JAMA Internal Medicine, 2014. Read source
Randomized trial; full PubMed abstract reviewed. 339 participants, 8 weeks. Symptom frequency endpoint; not a long-term safety comparison.
S03: WHI estrogen plus progestin principal results
Rossouw et al., JAMA, 2002. Read source
Randomized trial; full PubMed abstract reviewed. 16,608 women aged 50-79; oral CEE plus MPA. Mean 5.2-year report; regimen and population limits retained.
S04: WHI breast cancer incidence and mortality during long-term follow-up
Chlebowski et al., JAMA, 2020. Read source
Follow-up of two randomized trials; full PubMed abstract reviewed. 27,347 participants; more than 20-year median cumulative follow-up. Different uterine-status populations, not a direct comparison of regimens.
S05: WHI long-term all-cause and cause-specific mortality
Manson et al., JAMA, 2017. Read source
Follow-up of randomized trials; full PubMed abstract reviewed. 27,347 participants; 18-year cumulative follow-up, not 18 years of assigned treatment.
S06: Hormone therapy and venous thromboembolism in QResearch and CPRD
Vinogradova et al., BMJ, 2019. Read source
Nested case-control studies; full PubMed abstract reviewed. 80,396 VTE cases and 391,494 controls. Associations, not randomized route comparisons.
S07: Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol
Hodis et al., New England Journal of Medicine, 2016. Read source
Randomized trial; full PubMed abstract reviewed. 643 healthy women; median 5 years. Carotid-wall thickness was the primary endpoint, not heart attacks or survival.
S08: WHIMS estrogen plus progestin and dementia
Shumaker et al., JAMA, 2003. Read source
Randomized trial; full PubMed abstract reviewed. 4,532 women aged 65 or older; oral CEE plus MPA. Do not extrapolate directly to treatment at age 50.
S09: The 2020 genitourinary syndrome of menopause position statement
The North American Menopause Society, 2020. Read source
Consensus guideline; full PubMed abstract reviewed. Local treatments and uterine-protection distinction. Long-term endometrial trial data limited.
S10: AUA SUFU AUGS Guideline on Genitourinary Syndrome of Menopause
American Urological Association and partner societies, 2025. Read source
Guideline; full PubMed abstract reviewed. Local low-dose vaginal estrogen has the most robust evidence base; diagnosis excludes other causes. Full guideline PDF returned access error.
S11: Evidence-based guideline on premature ovarian insufficiency
ESHRE, ASRM, CREWHIRL and IMS, 2024/2025. Read source
Official full guideline webpage; relevant recommendations reviewed. POI differs from usual-age menopause; replacement generally recommended until usual menopause age, followed by individual reassessment.
S12: Global Consensus Position Statement on Testosterone Therapy for Women
Davis et al., Journal of Clinical Endocrinology and Metabolism, 2019. Read source
PubMed identity and official journal indexed recommendations reviewed. Limited to postmenopausal HSDD after assessment; long-term safety uncertain. Full text unavailable during this run.
S13: Compounded Bioidentical Menopausal Hormone Therapy
ACOG Clinical Consensus No. 6, 2023. Read source
Consensus; full PubMed abstract reviewed. FDA-approved products preferred when available; marketing does not establish safety or effectiveness.
S14: The 2023 nonhormone therapy position statement
The North American Menopause Society, 2023. Read source
Consensus guideline; full PubMed abstract reviewed. Several evidence-based options for vasomotor symptoms. Later regulatory updates checked separately.
S15: Vivelle-Dot prescribing information revised October 2026
U.S. Food and Drug Administration. Read source
Official label; boxed warning, indications and contraindications reviewed. Endometrial cancer boxed warning retained; systemic contraindications remain despite other labeling changes. One product example, not a class-wide label audit.
S16: FDA approves labeling changes to menopausal hormone therapy products
U.S. Food and Drug Administration, February 12, 2026. Read source
Official regulatory announcement reviewed. Initial six-product approval; do not imply every product changed that day or infer risk-free treatment.
S17: Hormone therapy for primary prevention of chronic conditions
U.S. Preventive Services Task Force, 2022. Read source
Official recommendation and population scope reviewed. Against use solely for primary prevention in asymptomatic postmenopausal people; excludes symptom treatment and premature/surgical menopause.
S18: Hormonal Options for Perimenopause A Clinician Toolkit
Piasta and Zewail, Obstetrics and Gynecology, 2026. Read source
Clinical perspective; PubMed abstract reviewed. Different physiology, bleeding and contraception needs; not a formal guideline or dosing basis here.
S19: Management of menopause-related vasomotor sleep and mood symptoms
ACOG Clinical Practice Guideline, 2026. Read source
Identity and full PubMed abstract reviewed. Current guideline exists; exact recommendation text and evidence tables not retrieved. Detailed recommendation claims held.
S20: Menopause transition and cardiovascular disease risk
El Khoudary et al., American Heart Association scientific statement, 2020. Read source
Scientific statement; full PubMed abstract reviewed. Midlife is an opportunity for cardiovascular risk assessment; does not establish hormone therapy as cardiovascular prevention.
S21: FDA adds boxed warning about serious liver injury with fezolinetant
U.S. Food and Drug Administration, December 16, 2024 update. Read source
Official drug safety update, relevant text reviewed. Rare serious liver injury and required laboratory monitoring.
S22: Drug Trials Snapshot LYNKUET
U.S. Food and Drug Administration. Read source
Official approval record, relevant text reviewed. Elinzanetant approval October 24, 2025; not a head-to-head comparison with hormone therapy.
S23: Lynkuet prescribing information at approval
U.S. Food and Drug Administration, October 2025. Read source
Official label; safety provisions independently reviewed. Baseline and 3-month liver tests; daytime impairment, pregnancy contraindication and seizure-history caution.